On October 10, 2024, Cytovale, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced that it has raised $100 million in Series D funding. The round was led by Sands Capital, with participation from new investor Canada Pension Plan Investment Board (CPP Investments), as well as existing investors Norwest Venture Partners, Global Health Investment Corporation, and Breakout Ventures. Wilson Sonsini Goodrich & Rosati advises Cytovale on intellectual property strategy generally and advised the company on IP matters related to the Series D financing. .

Cytovale’s IntelliSep test is the first and only U.S. Food and Drug Administration (FDA)-cleared cellular host diagnostic indicated for use in hospital emergency departments, where over 80 percent of sepsis cases present. The test, which takes only approximately eight minutes, provides clinicians with a first-ever look into the biology that causes sepsis, enabling care teams to quickly and confidently identify the proper diagnosis and deliver appropriate, patient-centered care. Cytovale will use the proceeds from the financing to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments and health systems nationwide.

The Wilson Sonsini team that advised Cytovale on IP matters related to the financing includes Matt Bresnahan, Maysam Pessian, Nicholas Tiee, and Ben Hoar.

For more information, please see Cytovale’s news release.